FCM
PRME icon

Fogel Capital Management’s Prime Medicine PRME Stock Holding History

Fogel Capital Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$24.7K – 56
2025
Q2 		$24.7K Buy
+10,000
New +$15.4K 0.01% 51

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fogel Capital Management's PRME Position: Q3 2025 in Review

Fogel Capital Management sold out of Prime Medicine (PRME) in Q3 2025, closing a stake of 10,000 shares — an estimated $24.7K sold.

Fogel Capital Management first reported a position in PRME in Q2 2025 and held it in 1 quarter. The position peaked at $24.7K in Q2 2025. 167 funds tracked by Wall St. Rank hold PRME as of Q3 2025.

  • Fogel Capital Management reported no remaining Prime Medicine position as of Q3 2025 after selling out during the quarter.
  • Fogel Capital Management sold 10,000 Prime Medicine shares in Q3 2025, an estimated $24.7K.
  • Fogel Capital Management first reported a position in Prime Medicine in Q2 2025 and held it in 1 quarter.
  • Fogel Capital Management's Prime Medicine position peaked at $24.7K in Q2 2025.
  • 167 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2025.

Based on Fogel Capital Management's 13F filing for Q3 2025, filed 21 Oct 2025.